Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving XOMA Royalty Corporation and its officers or directors [1] Group 1: Company Overview - XOMA Royalty Corporation is listed on NASDAQ under the ticker symbol XOMA [1] - The company is involved in a partnership with Rezolute, Inc. for the development of medical treatments [3] Group 2: Recent Developments - Rezolute, Inc. announced that its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism did not meet its primary endpoint, showing only a 45% reduction in hypoglycemia events at the highest dose, which was not statistically significant compared to a 40% improvement in the placebo group [3] - The study also failed to meet its key secondary endpoint, with a 25% reduction in time spent in hypoglycemia at the 10 mg/kg dose, again not statistically significant compared to a 5% increase in the placebo group [3] - Following this announcement, XOMA's stock price dropped by $7.82 per share, or 22.76%, closing at $25.39 per share on December 19, 2025 [3]

Core Viewpoint - XOMA Royalty Corporation announces the resignation of CFO Thomas Burns, who has been instrumental in the company's transition to a royalty aggregator, and appoints Jeffrey Trigilio as the new CFO to continue the company's growth strategy in the biotech sector [1][2]. Company Leadership Transition - Thomas Burns is stepping down after nearly two decades of service, with CEO Owen Hughes expressing gratitude for his contributions to the company's financial foundation and growth [2]. - Jeffrey Trigilio has been appointed as the new CFO, bringing extensive experience from various biotech companies and investment banks, including his recent role at Obsidian Therapeutics [2][3]. Strategic Direction - The leadership team, under Trigilio, aims to enhance the royalty portfolio through disciplined capital deployment, robust diligence, and innovative deal structuring to generate shareholder value [3]. - XOMA Royalty operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical companies, providing sellers with non-dilutive funding [3]. Portfolio Overview - XOMA Royalty's portfolio includes commercial assets such as VABYSMO, OJEMDA™, MIPLYFFA™, XACIATO™, IXINITY, and DSUVIA, with other assets being investigational compounds [6].

Core Insights - XOMA Royalty Corporation has amended its collaboration with Takeda, regaining a majority of the royalty interest in mezagitamab while diversifying its portfolio through a strategic royalty share transaction [1][2] Summary by Relevant Sections Collaboration with Takeda - The collaboration, originally established in 2006, has been amended to reduce Takeda's royalty and milestone payment obligations related to mezagitamab [1] - XOMA Royalty will now receive low to mid-single-digit royalties and milestone payments across nine development-stage assets in Takeda's externalized assets portfolio [1][2] Financial Implications - Prior to the amendment, XOMA Royalty held a mid-single-digit royalty and $16.25 million in potential milestones for mezagitamab [3] - Post-amendment, XOMA Royalty will retain a low single-digit royalty entitlement and up to $13.0 million in milestones for mezagitamab [3] Development-Stage Assets - The nine development-stage assets include: - **Osavampator**: Developed by Neurocrine Biosciences for major depressive disorder [4] - **Volixibat**: Developed by Mirum Pharmaceuticals for primary sclerosing cholangitis and primary biliary cholangitis [5] - **OHB-607**: A recombinant human IGF-1/IGFBP-3 for preventing bronchopulmonary dysplasia in premature infants, along with other early-stage assets from Oak Hill Bio [6] - **REC-4881**: An investigational MEK1/2 inhibitor for familial adenomatous polyposis, affecting approximately 50,000 people in the U.S. and Europe [7]

Core Insights - XOMA Royalty Corporation has announced an agreement to acquire Generation Bio Co. for $4.2913 per share, with additional contingent value rights (CVR) for stockholders [1][2][3] Acquisition Details - The acquisition involves a cash tender offer for all outstanding shares of Generation Bio common stock, with the closing expected in February 2026 [3][4] - Generation Bio's board has unanimously approved the merger, determining it to be in the best interests of stockholders [2][4] - Approximately 15% of Generation Bio stockholders have signed support agreements to tender their shares in the offer [4] Financial Aspects - The CVR entitles holders to potential payments based on various conditions, including net cash at closing exceeding $29 million and savings realized from XOMA Royalty's Cambridge office lease obligations [7] - Payments from Generation Bio's existing license agreement with Moderna will also be shared with CVR holders, potentially delivering up to 90% of such payments [7] Company Background - XOMA Royalty is a biotechnology royalty aggregator that acquires future economic rights associated with therapeutic candidates licensed to pharmaceutical companies [6] - Generation Bio focuses on delivering small interfering RNA (siRNA) therapies using cell-targeted lipid nanoparticles [8]

Core Viewpoint - XOMA Royalty Corporation has successfully completed the acquisition of Mural Oncology plc, with shareholders receiving $2.035 in cash per share as part of the transaction [1][2]. Acquisition Details - The acquisition was approved by Mural shareholders during a special meeting on October 24, 2025, and was sanctioned by the Irish High Court on December 3, 2025 [2]. - The acquisition became effective on December 5, 2025, following the delivery of the court order to the Irish Companies Registration Office [2]. Trading and Delisting - Mural's shares ceased trading on Nasdaq prior to the market opening on December 5, 2025, and the company plans to delist and deregister its shares under the Securities Exchange Act of 1934 [3]. Advisory Information - XOMA Royalty was advised by Gibson, Dunn & Crutcher LLP and Mason Hayes & Curran LLP, while Davy Corporate Finance UC acted as its financial advisor [4]. - Mural was advised by Lucid Capital Markets, LLC, with legal support from Wilmer Cutler Pickering Hale and Dorr LLP and Arthur Cox LLP [4]. Company Overview - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical or biotechnology companies [5]. - The company provides non-dilutive funding to sellers, enabling them to advance their internal drug candidates or for general corporate purposes [5].

Core Viewpoint - Mural Oncology plc has announced the effective completion of a scheme of arrangement under which XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, will acquire the entire issued share capital of Mural as of December 5, 2025 [1]. Group 1: Acquisition Details - The acquisition scheme became effective on December 5, 2025, allowing XRA 5 Corp. to acquire all shares of Mural [1]. - Distribution of cash consideration to Mural's shareholders is expected to begin shortly after the effective date, with completion anticipated by December 19, 2025 [2]. - Mural's shares were officially canceled from trading on the Nasdaq Global Market as of 8:00 PM (U.S. Eastern Time) on December 4, 2025 [3]. Group 2: Regulatory Compliance - The announcement complies with the Irish Takeover Rules, and the directors of Mural have confirmed the accuracy of the information provided [7]. - The announcement will be made available on Mural's website in accordance with Rule 26.1 of the Irish Takeover Rules [12].

Core Viewpoint - Mural Oncology plc has received approval from the High Court of Ireland for a scheme of arrangement that will allow XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, to acquire all issued shares of Mural [1] Group 1: Acquisition Details - The scheme and acquisition will take effect upon the delivery of the Court Order to the Irish Registrar of Companies [2] - The effective date for the acquisition is expected to be December 5, 2025, with trading of Mural shares on Nasdaq ceasing on December 4, 2025 [3] - The cancellation of Mural shares from trading on the Nasdaq Global Market is anticipated to occur at 8:00 PM (U.S. Eastern Time) on December 4, 2025 [3] Group 2: Financial Considerations - Distribution of cash consideration to scheme shareholders is expected to begin shortly after the effective date, with completion anticipated by December 19, 2025 [4]

Core Viewpoint - Mural Oncology plc has finalized the cash consideration for its shareholders at $2.035 per share as part of the acquisition by XOMA Royalty Corporation, with the additional price per share determined to be $0.000 [1][2]. Group 1: Acquisition Details - The acquisition involves XOMA Royalty's wholly-owned subsidiary, XRA 5 Corp., acquiring the entire issued and to be issued share capital of Mural under an Irish High Court sanctioned scheme of arrangement [2]. - The acquisition is expected to close in early December 2025, pending the satisfaction of closing conditions and the sanction of the scheme by the Irish High Court [3]. Group 2: Financial Implications - The total cash consideration payable to Mural shareholders upon closing of the acquisition will be $2.035 per share [1].

Core Insights - XOMA Royalty Corporation has completed the acquisition of LAVA Therapeutics N.V., with shareholders receiving $1.04 in cash per share and a contingent value right (CVR) [1][2] - The acquisition aligns with XOMA's strategy of enhancing its portfolio through partnerships with established oncology firms like Johnson & Johnson and Pfizer, potentially leading to significant value creation [2][3] Acquisition Details - The acquisition involved a total of 23,956,708 shares validly tendered, representing approximately 91.1% of the outstanding shares as of the final expiration date [2] - Following the acquisition, LAVA underwent a corporate reorganization, resulting in XOMA acquiring 100% of LAVA's shares, with remaining shareholders receiving the same cash and CVR consideration [3] Financial Aspects - LAVA shareholders are entitled to receive 75% of net proceeds from LAVA's partnered assets and any out-licensed or sold unpartnered programs, along with potential additional payments of up to approximately $0.23 per CVR [1][2] - The acquisition is expected to drive future milestones and royalties, enhancing the financial outlook for both XOMA and LAVA CVR holders [2] Legal and Advisory Information - XOMA Royalty was advised by Gibson, Dunn & Crutcher LLP and Loyens & Loeff N.V., while LAVA was represented by Leerink Partners and Cooley LLP [4]

Core Insights - XOMA Royalty reported a quarterly loss of $0.35 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.02, representing an earnings surprise of -1,650% [1] - The company generated revenues of $9.35 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 25.7%, but showing an increase from $7.2 million in the same quarter last year [2] - XOMA Royalty shares have increased by approximately 31.2% year-to-date, outperforming the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $13.46 million, and for the current fiscal year, it is $0.62 on revenues of $55.05 million [7] - The estimate revisions trend for XOMA Royalty was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which XOMA Royalty belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - VistaGen Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.51 per share, reflecting a year-over-year change of -21.4% [9]